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Abstract
The assessment of safety is an important aspect of the evaluation of new therapies in clinical trials,
with analyses of adverse events being an essential part of this. Standard methods for the analysis of ad-
verse events such as the incidence proportion, i.e. the number of patients with a specific adverse event out
of all patients in the treatment groups, do not account for both varying follow-up times and competing
risks. Alternative approaches such as the Aalen-Johansen estimator of the cumulative incidence function
have been suggested. Theoretical arguments and numerical evaluations support the application of these
more advanced methodology, but as yet there is to our knowledge only insufficient empirical evidence
whether these methods would lead to different conclusions in safety evaluations. The Survival analysis
for AdVerse events with VarYing follow-up times (SAVVY) project strives to close this gap in evidence
by conducting a meta-analytical study to assess the impact of the methodology on the conclusion of the
safety assessment empirically. Here we present the rationale and statistical concept of the empirical study
conducted as part of the SAVVY project. The statistical methods are presented in unified notation and
examples of their implementation in R and SAS are provided.
Keywords: Clinical trials; Cumulative incidence function; Drug safety; Meta-regression; Risk-benefit
assessment
1 Introduction
Time-to-event or survival endpoints are commonly encountered in clinical trials, and some literature searches
have found that survival analysis is the most common advanced statistical technique in medical research
(Horton and Switzer, 2005; Sato et al., 2017). Censoring is arguably the major reason to use survival
methodology, since statistical inference that does not account for censoring will, in general, be biased.
∗Corresponding author: Tim Friede, Institut fu¨r Medizinische Statistik, Universita¨tsmedizin Go¨ttingen, Humboldtallee 32, 37073
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Primary efficacy outcomes in time-to-event studies are often comprehensive outcomes such as overall or
progression-free survival (Schumacher et al., 2016), and Kaplan-Meier curves are commonly used to es-
timate survival probabilities, while the log-rank test and/or the Cox model are used to compare treatment
groups (Gosho et al., 2018). Here, a ‘comprehensive outcome’ is a time-to-event outcome that every patient
experiences, possibly after study closure which would then result in an administratively censored obser-
vation. There are, however, concerns that many published Kaplan-Meier curves are subject to a so-called
‘competing risk bias’ (van Walraven and McAlister, 2016; Schumacher et al., 2016). Such bias arises for
non-comprehensive time-to-event outcomes, and Kaplan-Meier will then overestimate cumulative event
probabilities.
Safety evaluation is an essential aspect of clinical trials beyond the efficacy evaluation of new therapies
(Yang et al., 2019) with primary focus on quantifying the incidence of adverse events (AEs). But the use
of sophisticated survival methodology in practice does not translate to AE analyses, and, arguably, the
major workhorses to quantify AE incidence are the incidence proportion, i.e., the number of patients with
an observed AE (of a certain type) divided by group size, and the (exposure adjusted) incidence density,
which divides by cumulative patient-time at risk. This gap, using time-to-event methodology for efficacy
analyses but not for AE analyses, has been criticized by a number of authors for some time already, see
(O’Neill, 1987; Allignol et al., 2016; Bender et al., 2016; Unkel et al., 2019). The issue is that the incidence
proportion estimates the probability that a patient experiences an AE and that it is observed before censoring
which is less than the absolute AE risk, i.e., the probability of experiencing the AE. Closely related to this
issue are varying follow-up times which further complicate using incidence proportions, see, in particular,
Bender et al. (2016).
The incidence density, on the other hand, accounts for both censoring and varying follow-up times
by considering patient-time at risk in the denominator rather than the simpler number of patients. The
incidence density is not an estimator of absolute AE risk, but rather of the AE hazard under a constant
hazard assumption. This rather restrictive parametric assumption has been repeatedly criticized (Kraemer,
2009; Bender and Beckmann, 2019). The Kaplan-Meier curve has been considered as a non-parametric
alternative on the probability scale (Siddiqui, 2009; Crowe et al., 2009), but is subject to the aforementioned
competing risk bias. This would also be true for its parametric counterpart, when translating the incidence
density onto the probability scale.
The nature of competing risk bias is that one minus a Kaplan-Meier curve approximates an empirical
distribution function, where the approximation is due to incompletely observed data as a consequence of
censoring. Empirical distribution functions eventually reach 100%. For estimating absolute AE risk by the
Kaplan-Meier method, the consequence is that one implicitly assumes that every patient would experience
the AE under consideration eventually. However, this does not hold true for patients who die before the
AE, and the absolute AE risk is consequently overestimated. Here, ‘death before AE’ acts as a competing
event (or ‘competing risk’) and must be accounted for in the statistical analysis. For instance, Allignol et
al. (Allignol et al., 2016) demonstrate in a real data analysis that a simple parametric AE analysis using
incidence densities but accounting for competing events may outperform a Kaplan-Meier analysis.
So, the concern is that quantifying absolute AE risk may be either underestimated (incidence propor-
tions) or overestimated (Kaplan-Meier, incidence densities). The issues are mainly censoring, varying
follow-up times, competing events and, in the case of incidence densities, a possibly too restrictive para-
metric model. Here, a non-parametric benchmark method is provided by the Aalen-Johansen estimator
(Aalen and Johansen, 1978) which generalizes the Kaplan-Meier estimator to multiple event types, see
Beyersmann and Schmoor (2019) for a recent textbook treatment in the context of AE. The magnitude of
such bias in practice on, e.g., AE frequency categories will, however, depend on the frequency of competing
events, the magnitude of censoring or the difference in follow-up. In terms of between-group comparisons,
the impact of, say, dividing two metrics that both underestimate or both overestimate is also unclear.
The SAVVY (Survival analysis for AdVerse events with VarYing follow-up times) project strives to
close this gap in evidence by conducting a meta-analytical study. In this project, participating sponsor
companies and organizations (in the following called sponsors) select randomized controlled clinical trials
of special interest, particularly those with varying follow-up times between patients and possibly between
treatment arms. This includes studies in different therapeutic areas. Within studies, one or more AEs of
interest will be selected. Here we present the rationale and statistical concept. The statistical methods
are presented in unified notation and the implementation in R and SAS is described adding some interest
2
to this work beyond presenting concepts of the main study. While basic methodological considerations
on AE analyses, censoring, varying follow-up times and competing risks have been discussed elsewhere,
see, e.g., Unkel et al. (2019) and Beyersmann and Schmoor (2019), this paper offers additional detailed
insights by considering practically relevant questions such as which kind of event should be viewed as
competing and which one as a standard censoring event. For instance, Unkel et al. (2019) briefly touch
upon the question whether diagnosed progression is a competing event or rather a censoring event, and if
the latter, whether such censoring is informative, and, finally, what the impact on AE analyses is. Here,
Section 2.2 offers further guidance, also distinguishing between a “hard” competing event definition and
a more encompassing one. Furthermore, an important meta-analytical issue is that estimates are typically
weighted by the inverse of an estimated variance which is not straightforward in the setting here, since the
aim is to compare different methodological approaches performed within one study. As a consequence,
the variance of the difference measure between, e.g., Kaplan-Meier and incidence proportion is required.
This difficulty has, e.g., also been faced (but not solved) by Lacny et al. (2015, 2018), and Section 4.4 will
explain how to bootstrap these variances.
The remainder of the paper is organized as follows. Section 2 discusses in detail the definition of AEs
and of competing events and will also briefly consider composite events. The latter will be included to in-
vestigate the impact of ignoring censoringwithout the complication of competing events. Section 3 explains
the organization of the data analyses within SAVVY and may serve as a template for future investigations
of related questions. Here, an important aspect is that trial level analyses will be run at sponsors’ sites, but
meta-analyses will be run centrally by the academic project collaborators. The statistical methods on trial
level are collected in Section 4. This section, in particular, explains how SAVVY will quantify and account
for different lengths of follow-up and makes a connection between the different methods of estimation. For
instance, the incidence proportion will equal the Aalen-Johansen estimator evaluated at the largest observed
time in the absence of censoring. Details of the meta-analyses to be performed are in Section 5. This sec-
tion, in particular, addresses the multitude of comparisons to be considered as well as assessment of bias
and heterogeneity. A brief discussion is in Section 6, also addressing the question of recurrent AEs, and
software code is provided in the online supplement.
2 Definition of events
2.1 Adverse events
According to the Good Clinical Practice (GCP) guideline an AE is defined as “any untoward medical oc-
currence in a patient or clinical investigation subject administered a pharmaceutical product and which does
not necessarily have a causal relationship with this treatment” (Committee for Human Medicinal Prod-
ucts, 2016). In this meta-analytic study, the choice of AEs within the selected clinical trials is left to the
sponsor. These may be defined as AEs of special interest, as belonging to a specific Medical Dictionary
for Regulatory Activities (MedDRA) system organ class or preferred term, as being severe according to
a toxicity grading, as being related to the investigational product, as serious, or as a combination of these
characteristics.
Often sponsors will select as AEs the adverse drug reactions presented in the core data sheet for a first
submission for drug approval, and select the studies that supported the frequency derivation.
These choices may result in a range of frequency, from common AEs to rare ones. It is expected
that differences between the methodological approaches will be less marked with very rare AEs or very
common AEs. So, grouping of different rare AE types into one AE category would be permissible for
studying methodological differences. Making use of this frequency range (from rare to more common per
selected trial) allows to further investigate the impact of the frequency on the differences between statistical
analysis methods. Ideally, AEs of different frequencies per trial should be chosen, e.g. around 30%, around
10%, and around 1%.
The investigation is restricted to the analysis of the occurrence of the first AE of a specific type and
will not consider the analysis of recurrent events. However, the relevance of the present investigation for
recurrent AEs will also be considered in Section 6.
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2.2 Competing events definition
Competing events are events that preclude the occurrence of the AE of interest. For instance, if in a clinical
trial the focus is on estimating the probability of headache, patients who die without prior headache report
will never report headache. It is obvious that death is a competing event with respect to the occurrence
of headache. However, defining a general rule as to which events should be treated as a competing event,
without specific insight into the specific event of interest and study at hand, is challenging.
As a rule of thumb, any event that both a) would be viewed from a patient perspective as an event of
his/her course of disease or treatment, and b) would stop the recording of the AE of interest should be viewed
as a competing event. This situation would typically occur when a patient discontinues the treatment due to
another AE judged by the investigator as too severe to continue treatment, or when the patient discontinues
treatment or study due to progression/lack of efficacy, and, as a consequence, the recording of AEs ends.
Hence, if end of follow-up for AEs, withdrawal of consent or discontinuation is disease or treatment-related,
this would be handled as a competing event. See Lawless and Cook (2019) for related considerations.
In contrast to a competing event, the time-to-event is censored if the patient reaches the designated end
of follow-up without having had the AE of interest or a competing event as defined above. This situation is
present with administrative censoring due to the regular end of the trial or the end of follow-up for AEs due
to the planned end of treatment (often end of treatment plus an additional fixed time interval, e.g., 30 days)
not triggered by the course of disease.
In the analysis, the different competing events will be combined into one composite competing event,
as the aim is to compare different methods to quantify the risk of an interesting AE and not the risk of a
competing event of a specific type.
There is much debate among statisticians on the question which events should be analyzed as competing
events and which events should lead to censoring the time-to-event. In practice, there is no discussion that
death without the previous occurrence of the interesting AE acts as a competing event with respect to AE
occurrence. The reason is that after death the AE can definitely not occur any more, and in this sense “death
without prior AE” is a so-called “hard” competing event. However, the other events mentioned above as
loss to follow-up, withdrawal of consent or treatment discontinuation can be regarded as so-called “soft”
competing events in the sense that, thereafter, the interesting AE in principle still could occur, but cannot
be observed due to end of follow-up. Discussions therefore arise around the question whether to treat these
soft competing events as censoring or as competing event. One extra concern here is that, e.g., treatment
discontinuation will likely alter the AE hazard. See also Unkel et al. (2019) on how these aspects connect
to the current debate on estimands.
Therefore, two different approaches will be compared in this project. In a first approach (called “all-
events approach” in the following), all competing events mentioned above will be combined and analyzed
as a single competing event and only patients reaching the designated end-of-follow-upwith neither former
AE of interest nor competing event as defined above will contribute as censored observation. In a second
approach (referred to as “death-only approach” in the following), only the hard competing event (i.e. death
without prior AE of interest) will be analyzed as competing event, and the soft competing events will be
analyzed as censored observations.
2.3 Composite events
Additionally to the statistical analyses of AEs considering competing events, further analyses encompassing
both the AE of interest and the competing event as composite event will be performed, thereby addressing
the composite estimand (Unkel et al., 2019; Rufibach, 2019). The time to the composite event will be
defined as time to the interesting AE or to the competing event whatever occurs first, and patients with
neither the interesting AE nor the competing event will contribute a censored time-to-event. The rationale
for the inclusion of this approach is to gauge the impact of using time-to-event methodology to account for
varying follow-up times without the methodological complication of competing events. To this end, time-
to-event analyses accounting for censoring will be compared to the traditionally used incidence proportion.
4
3 Organization of the data analysis
The SAVVY project group consists of the academic project collaborators who planned the statistical anal-
yses (in the following referred to as the “analysis center”) and the participating sponsors, who contribute
randomized clinical trial data for analysis. In the SAVVY project, the data analysis involves the following
steps:
1. Pre-registration: Confidential pre-registration of the clinical trials selected by the sponsors with the
analysis center and allocation of a SAVVY trial identifier (ID) to registered trials by the analysis
center
2. Individual trial analysis: Analysis of the registered trials at sponsor’s site using code provided by the
analysis center and transfer of aggregated trial level results to the analysis center
3. Meta-analysis: Meta-analysis of trial level results at the analysis center
In the following, these steps will be considered one by one in more detail.
Pre-registration The sponsors select the randomized clinical trials and the AEs they wish to enter into
this project. In order to avoid selection bias, these trials have to be confidentially pre-registered with the
analysis center before running the analyses. For the identification of the trials, a unique trial ID according
to a publicly accessible trial registry, e.g. clinicaltrials.gov or the German Clinical Trials Register, has
to be provided together with some characteristics of the trial and the selected AEs (see Table 1). The
identification of the trials included will not be disclosed otherwise. In publications or presentations it will
only be reported that studies have been identified to the analysis center. The analysis center will handle
any information related to trial level data in a confidential manner. Also, the exchange of trial related
information between the sponsor and the analysis center will take place in a secured manner following the
sponsors’ individual policies regarding the secure exchange of confidential information.
To register the trials and the AEs for the SAVVY project, a spreadsheet is filled in by the sponsor
containing one row per AE of interest with the main AE characteristics, e.g. seriousness, severity, MedDRA
system organ class (SOC), MedDRA preferred term (PT). If a sponsor does not want to provide a particular
information or if the information is not relevant due to the particular grouping applied, “NA” for “not
applicable” can be used. Table 1 shows the characteristics of the selected trials and AEs that will be
captured.
After receipt of the registration sheet, a SAVVY trial ID will be allocated to the trial by the analysis
center. The SAVVY IDwill be entered into the study characteristics spreadsheet and returned to the sponsor.
Individual trial analysis The analyses of the individual clinical trials will be done at sponsor’s site using
SAS or R code provided by the analysis center. Therefore, it is not required to release any individual patient
data to the analysis center. Only aggregated data, summarizing the results of the analyses, will be shared
with the analysis center. The analysis center will not share the aggregated data of one sponsor with any other
sponsor. A manual is provided by the analysis center to the sponsor describing what needs to be done after
receipt of the SAVVY trial ID and the program code. As a prerequisite, at the sponsors’ sites, the individual
clinical trials data sets must be brought into a format which allows the application of the provided SAS or
R code. The required data structure is simple, similar to that of a standard survival analysis, and shown in
Table 2.
For each trial one dataset is needed in which all AE specific data for the selected AEs are set below
each other. The different AEs are distinguished by the AE ID, matching the AE ID given in the study
characteristics table filled for trial pre-registration. The treatment group ID will be used by the SAS or R
code but is not included in the results where experimental and control groups are coded as “A” and “B”,
respectively. Observations with missing data, negative event times or type of event not in {0, 1, 2, 3} are
automatically excluded from the analyses.
The SAVVY trial ID is inserted in the SAS or R code. The program returns the aggregated data summa-
rizing the results of the statistical analysis methods described in Section 4 and the results of some further
descriptive analyses on the AE and the competing event, namely mean, median, minimum and maximum
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Table 1: Characteristics of the selected trials and AEs captured during pre-registration
Trial / AE characteristic Explanation, possible entries
Unique trial ID Clinical trials registry number according to a publicly
accessible trial registry, e.g. clinicaltrials.gov, German
Clinical Trials Register
Indication Indication / therapeutic area investigated in the trial
Type of comparison Active or placebo controlled
End of the trial Year of last patient / last visit of the trial
Maximum follow-up time for primary Maximum follow-up time of the patients for recording the
efficacy endpoint primary efficacy endpoint (in days)
AE ID AE identifier, incremental AE numbering (from 1 to total
number of selected AEs) per trial
Maximum follow-up time for AE Maximum follow-up time of the patients for recording
the AE (in days)
Seriousness of AE Specify if serious AE, any AE or NA
Severity of AE Specify CTCAE toxicity grade (e.g. ≥ 3), any toxicity
grade or NA
MedDRA system organ class (SOC) of AE Specify SOC(s), any SOC or NA
MedDRA preferred term (PT) of AE Specify PT(s), any PT or NA
Special interest AE Specify special interest AE, any AE or NA
Hard competing events Specify the type(s) of the hard competing event(s) as
defined in Section 2.2, e.g., death
Soft competing events Specify the type(s) of the soft competing event(s) as
defined in Section 2.2, e.g., end of treatment, withdrawal
of consent, progression
event time by type of event and overall, and the total numbers of AEs, competing events, and censored ob-
servations, each overall and per treatment group. The dataset containing all results is named automatically
identical to the SAVVY trial ID and is sent to the analysis center for further processing.
Meta-analysis Once the results of all registered trials are received, the analysis center performs the meta-
analyses described in Section 5 of the estimated parameters described in Section 4. The results of the meta-
analyses will be presented and discussed within the SAVVY project group without identifying individual
trials and sponsors.
Table 2: Required data structure for application of program code
Column Description
AE ID Number from 1 up to the number of selected AEs within the trial
Patient ID Trial specific unique patient ID
Treatment group ID Identifying which treatment is experimental and which is control
Time to event In days
Type of event 1=AE of interest
2=hard competing event
3=soft competing event
0=censored
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4 Statistical methods on trial level
4.1 Quantifying length of follow-up
We will use two approaches to both quantify length of follow-up and to study its impact on analysing the
occurrence of AEs. The first approach is guided by the implicit choice made when calculating incidence
proportions. The second approach is guided by the concern that overly small risk sets late in time may lead
to unstable probability estimators (Pocock et al., 2002).
The first approach is to choose a time τA as the largest observed time (censored or AE or competing
event) which was (if observed AE) or could have been (if censored or competing event) an observed AE
time in group A. Time point τB is defined analogously for group B. Then one step to account for different
lengths of follow-up between groups is to restrict statistical inference to the smaller of the two time points.
Hence, let τ = min(τA, τB). The motivation behind this approach is two-fold: Firstly, the commonly
used incidence proportions are calculated in the complete data set, i.e., for the data available on [0, τA]
and [0, τB], respectively. Secondly, group comparisons for time-to-event data are typically restricted to the
smaller of these two time intervals only. For instance, the common log-rank test only compares groups as
long as the risk sets are non-empty in both groups.
The second approach follows a suggestion of Pocock et al. (2002). It covers a range of choices for
quantifying length of follow-up and will depend on the proportion of patients still at risk. So, additionally,
choose τ˜A(p) = τ˜A as the time such that 100 ·p%of all patients in group A are still at risk just prior time τ˜A
and may have an observed event at time τ˜A, p ∈ (0, 1). To be precise, let τ˜A be the 100 · p%-quantile of the
usual empirical distribution function Fˆ of the observed times (irrespective of censoring status),
τ˜A = inf{t : Fˆ (t) ≥ p}.
Choose τ˜B analogously in group B and let τ˜ = min(τ˜A, τ˜B). We will consider p ∈ {0.3, 0.6, 0.9}. The
relationship between τ˜A and τA is that both time points coincide for the choice of p = 1.
We also note that the different choices of τ account for different time horizons underlying the estimation
methods within groups, but they do not account for differential drop-out between groups. It is, e.g., possible
that τA = τB, but that drop-out rates differ between groups. Such differential drop-out would therefore be
potentially treatment group-related, suggesting to handle drop-outs as competing risks, see Section 2.2.
4.2 One-sample estimators
Methods are exemplarily discussed for group A and for τ . The estimators of “absolute AE risk” that we
will consider fall into three groups (Allignol et al., 2016). Firstly, the incidence proportion accounts for
competing risks but not for censoring (Equation (1) below). Secondly, one minus the Kaplan-Meier esti-
mator accounts for censoring but not for competing risks (Equation (4)), and this is also true for a standard
conversion of the incidence density to a probability (Equation (3)). Thirdly, the Aalen-Johansen estimator
generalizes the Kaplan-Meier estimator to competing risks and will later serve as a benchmark or method
of choice for nonparametric estimation of the cumulative AE probability. The connection to the incidence
proportion is that both coincide in the absence of censoring. The connection to one minus the Kaplan-Meier
estimator is that both coincide in the absence of competing risks. A parametric counterpart (Equation (7)) of
the Aalen-Johansen estimator (Equation (8)) based on incidence densities is also considered. The incidence
proportion divides the number of patients with an observed AE on [0, τ ] in group A by the number nA of
patients in group A. More precisely, introduce individual first-AE-counting processes
Ni(t) ∈ {0, 1}, i ∈ {1, . . . , nA}, t ∈ [0, τ ], Ni(0) = 0,
where Ni(t) = 1 denotes that an AE has been observed for patient i in the time interval [0, t] and that no
competing event has been observed before the AE. Analogously, let
N¯i(t) ∈ {0, 1}, i ∈ {1, . . . , nA}, t ∈ [0, τ ], N¯i(0) = 0,
denote i’s counting process of observed competing events. Because we consider time-to-first-event and
type-of-first-event, we have that
Ni(t) + N¯i(t) ≤ 1
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and both Ni(t) and N¯i(t) change their value from 0 to 1 at most once, when a time-to-first-event has been
observed. The aggregated processes are
NA(t) =
nA∑
i=1
Ni(t), N¯A(t) =
nA∑
i=1
N¯i(t).
In the absence of censoring, the sum of the two aggregated processes will eventually be equal to nA, but in
general we have NA(∞) + N¯A(∞) ≤ nA. The incidence proportion now is
IPA(τ) =
NA(τ)
nA
. (1)
The incidence density has the same numerator, but divides by person-time-at-risk. Again, to be precise,
introduce individual at-risk-processes
Yi(t) ∈ {0, 1}, i ∈ {1, . . . , nA}, t ∈ [0, τ ], Yi(0) = 1,
where, for t > 0, Yi(t) = 1 denotes that the patient is still under observation on [0, t) and that neither an
AE nor a competing event have happend on [0, t). Note that the at-risk-processes are left-continuous, such
that Yi(t) denotes the at-risk status just prior time t. If Yi(t) = 1, an event may happen and be observed at
time t. Otherwise, Yi(t) = 0. The incidence density now is
IDA(τ) =
NA(τ)∫ τ
0
∑nA
i=1 Yi(u) du
. (2)
The incidence density is not a probability, but estimates the AE hazard with values in [0,∞) under a constant
hazard assumption. A typical transformation of this estimator onto the probability scale is
1− exp (−IDA(τ) · τ) . (3)
Assuming a constant AE hazard, estimator (3) estimates the same quantity as one minus the Kaplan-Meier
estimator, which only codes observed AEs as an event and censors anything else. To be precise, introduce
increments
∆Ni(t) = Ni(t)− lim
uրt
Ni(u),
which equal one, if an AE (before any competing event) is observed for patient i at time t, and∆Ni(t) = 0
otherwise. Defining∆N¯i(t) analogously, the increments of the aggregated processes are
∆NA(t) =
nA∑
i=1
∆Ni(t), ∆N¯A(t) =
nA∑
i=1
∆N¯i(t).
The size of the risk set is
YA(t) =
nA∑
i=1
Yi(t),
and oneminus the Kaplan-Meier estimator which only codes observedAEs as an event and censors anything
else can be expressed as
1− SˆA(τ) = 1−
∏
u∈(0,τ ]
(
1−
∆NA(u)
YA(u)
)
= 1−
∏
u∈(0,τ ]
(
1−∆ΛˆA(u)
)
. (4)
Here,∆ΛˆA(u) is the increment of the nonparametric Nelson-Aalen estimator of the cumulative AE hazard
ΛˆA(τ) =
∑
u∈(0,τ ]
∆NA(u)
YA(u)
, (5)
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where the product in (4) and the sum in (5) is over all observed, unique event times u. Also note that we are
slightly abusing notation in (4), because SˆA(τ) is not estimating a proper survival function because of the
presence of competing risks. The Nelson-Aalen estimator, however, is a proper estimator of the cumulative
AE hazard. Assuming a constant AE hazard, ΛˆA(τ) and IDA(τ) · τ estimate the same quantity.
Accounting for competing risks now requires to acknowledge that there also is a competing hazard. To
begin, we introduce a competing incidence density
IDA(τ) =
N¯A(τ)∫ τ
0
∑nA
i=1 Yi(u) du
. (6)
Also using IDA(τ) as defined above, we obtain an estimator of the cumulative AE probability based on
incidence densities and accounting for competing risks,
pˆID;A(τ) =
IDA(τ)
IDA(τ) + IDA(τ)
(
1− exp(−τ · [IDA(τ) + IDA(τ)])
)
. (7)
The connection of this estimator to the incidence proportion is that the leading factor on the right hand
side of the previous display equals IPA(τ) in the absence of censoring and if τ = τA (Beyersmann and
Schrade, 2017). In words, both of these quantities estimate the anytime-AE-probability in this situation.
In the presence of censoring, quantity (7) estimates the cumulative AE probability assuming all hazards to
be constant. The nonparametric counterpart is the Aalen-Johansen estimator of the so-called cumulative
incidence function,
CIFA(τ) =
∑
u∈(0,τ ]
∏
v∈(0,u)
(
1−∆ΛˆA(v)−∆ΛˆA(v)
)
∆ΛˆA(u), (8)
where ∆ΛˆA(v) now is the increment of the competing Nelson-Aalen estimator in analogy to IDA. Note
that we have again slightly abused notation, writing CIFA(τ), although this quantity is an estimator.
4.3 Two-sample Comparisons
In principle, many methods of two-sample comparisons are conceivable. We here aim to consider one
method that applies to all one-sample estimators and provides a quantification of risk differences and relative
risks, where risk here refers to a probability estimator as defined earlier. To this end, assume that we have
estimators
qˆA, vˆar(qˆA) = s
2
A, qˆB, vˆar(qˆB) = s
2
B, (9)
where qˆA and qˆB are probability estimators within groups. That is, we have one line of values (9) for
each time point for the incidence proportion, one line of values for each time point for incidence densities
(transformed onto probability scale) etc., for each estimation method discussed in Section 4.2 and for each
evaluation time point defined in Section 4.1. Then, we estimate the risk difference by
RˆD = qˆA − qˆB (10)
with
s2 = vˆar
(
RˆD
)
= vˆar(qˆA) + vˆar(qˆB) (11)
and approximate 95% confidence interval
RˆD ± z0.975 · s, (12)
where z0.975 is the 0.975 quantile of a standard normal distribution.
Relative risks are estimated by
RˆR =
qˆA
qˆB
, (13)
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and we base variance estimation and construction of approximate confidence intervals on a log-transformation.
So, e.g., using the delta method
vˆar (log qˆA) =
(
1
qˆA
)2
vˆar(qˆA) = σˆ
2
A (14)
and
vˆar (log qˆA − log qˆB) = σˆ
2
A + σˆ
2
B = σˆ
2. (15)
This leads to the backtransformed approximate 95% confidence interval
RˆR · exp (±z0.975 · σˆ) . (16)
The primary comparison of methods will be based on probability estimators as explained. However,
because of the omnipresence of hazard ratios for group comparisons, we will also consider comparisons on
the hazard scale as detailed below:
• An estimated hazard ratio (output from standard Cox software) only coding AEs as “observed event”,
together with an estimator of its variance and a confidence interval for the hazard ratio.
• Ditto for the competing event, now only coding competing events as “observed event”. One rationale
here is to check whether relevant signals on the hazard scale would have been missed by ignoring
competing risks. We reiterate that, as for all competing event analyses, this will be done with the hard
and the soft definition given in Section 2.2.
• Ratios of incidence densities for AEs, with variance estimation analogous to above. The rationale
here is to check whether the simple constant hazard framework, although potentially misspecified,
leads to a reasonable approximation of the hazard ratio estimated in semi-parametric fashion.
• Ratios of incidence densities for competing events.
• Ratios of Nelson-Aalen estimators for AEs, with variance estimation analogous to above. The ratio-
nale here is to compare the usual hazard ratio estimator not only with a very simple parametric coun-
terpart, but also with a fully non-parametric competitor. Under a proportional hazards assumption,
the ratio of Nelson-Aalen estimators also estimates the hazard ratio, but not under non-proportional
hazards (Andersen, 1983).
• Ditto for the competing event.
4.4 Assessment of differences of estimators
The estimators in (9) and the derived information on estimated risk differences and risk ratios are of standard
input form for a meta-analysis. However, the aim is a methodological comparison of different methods for
quantifying AE risk when applied to the very same data. To this end, the information on variances so far
does not suffice, but what we need is an estimator of the variance between, e.g., the incidence proportion
and the Aalen-Johansen estimator when calculated on the same data set. As is obvious from the formulae
in Subsection 4.2, such estimators will in general be dependent. Closed form variance estimators might
be obtained using the functional delta method (Gill and Johansen, 1990), but one would need to derive
and implement such estimators for every single methodological comparison. We have therefore decided to
follow the advice of Andersen et al. (2012) and to resort to bootstrap variances, drawing with replacement
from the individual patients under an i.i.d. set-up. We also note that in a meta-analysis of published data
on the overestimation of the cumulative revision arthroplasty using a Kaplan-Meier-type estimator, Lacny
et al. (2015) used common approximations of the estimated variance of the hazard ratio for this purpose.
However, this approach estimates a different variance as the correlation structure is not accounted for.
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4.5 Implementation
The estimators displayed in the Sections 4.2 and 4.3 are readily available in the statistical software SAS
(SAS Institute, Cary, NC, US) and R (R Core Team, 2018). The implementation of the estimators of the
incidence proportion and the two estimators based on the incidence density is straightforward by the use of
the formulae. In SAS software the proc lifetest calculates the one minus Kaplan-Meier estimator. In
R it can either be obtained by the survfit function of the survival package (Therneau and Grambsch,
2000) or, as it is a special case of a competing risk setting, the etm function of the identically named
package (Allignol et al., 2011) can also be used to calculate both one minus the Kaplan-Meier estimator
and the Aalen-Johansen estimator. Depending on which SAS version is used the Aalen-Johansen estimator
can, on the one hand, be computed by the predefined %CIF Macro. On the other hand, in newer versions
of SAS software the proc lifetest specifying the event of interest in the option failcode can be
used.
The first part of the two-sample comparisons, the risk differences and relative risks with corresponding
variances, can be directly calculated by implementing the formulae. The Cox model and therefore the esti-
mated hazard ratio may be obtained by the use of the proc phreg in SAS and with the function coxph
in R. In oder to estimate (event-specific) hazard ratios, e.g., for AE, a well known coding method is to also
code observed competing events as “censored”. A brief look at the simple incidence densities illustrates
correctness of this method for analyzing hazards. The estimator of the cumulative AE probability in (7)
demonstrates that all hazards enter probability calculations and hence, the “code as censored” approach
is only available on the hazard level. In both of the software, it can be easily switched which event is of
interest, such that the hazard analysis of the competing event can as easily be obtained. The ratios of the
incidence densities for the adverse as well as for the competing event are easily calculated once the inci-
dence density for the one-sample estimators have been saved. The proc lifetest with the nelson
option gives the Nelson-Aalen estimator. Moreover, the mvna function of the mvna package (Allignol
et al., 2008) returns this estimator in R.
SAS macro code and the corresponding function in R is available as supplementary material. The main
macro code has been written in SAS 9.4 software and checked in R by one of the authors (RS). It has
subsequently been checked in a small scale pilot study (VJ, KR, CS).
5 Meta-analysis
Once the trial level data have been analysed using the methods described in Section 4, results will be
summarized across trials using the approaches listed below. Whereas individual trial data analyses will be
run within the sponsor company, meta-analyses will be run on the calculated probability and hazard (ratio)
estimates centrally at the analysis center, i.e. the institutions of the academic project group members.
5.1 Method comparisons
Table 3 gives an overview of the planned method comparisons. We will distinguish between the two types
of the competing events introduced in Section 2.2, i.e., all comparisons will be performed for both types
of competing events (death-only and all-events). Thereby, the main interest is in the ‘all-events’ competing
event. Especially, the comparison of Aalen-Johansen estimators based on the different competing event
definitions is of interest. The two Aalen-Johansen estimators will be compared for the AE as well as for the
competing event. Moreover, the comparisons in terms of hazard ratios will be conducted for the AE and for
the competing event. All comparisons are conducted at the five follow-up times as defined in Section 4.1
and not only at the final time-point.
5.2 Assessment of bias
The bias of the estimators will be assessed by comparison with the benchmark estimator. This will be
assessed visually using Bland-Altman plots of the AE probability, the risk difference and the (log) rela-
tive risks (Altman and Bland, 1983). As we consider a comparison of an estimator to a benchmark, the
benchmark estimator is plotted on the x-axis instead of the mean (Krouwer, 2008). With these plots, both
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Table 3: Planned comparisons. The quantities marked with ⋆ are calculated in both groups.
Target quantity Benchmark compared against
AE probability ⋆ Aalen-Johansen Incidence Proportion
Aalen-Johansen Probability Transform Incidence Density
Aalen-Johansen 1-Kaplan-Meier
Aalen-Johansen Probability Transform Incidence
Density accounting for competing events
Composite endpoint ⋆ 1-Kaplan-Meier Incidence Proportion
Hazard Ratio Cox Ratio Incidence densities
Cox Ratio Nelson-Aalen estimators
the one-sample (AE probability) as well as the two-sample (risk difference, relative risk) situation can be
considered.
5.3 Frequency categories
For the one-sample estimators, the possible change in frequency categories depending on estimation method
will also be investigated. According to the European Commission’s guideline on summary of product
characteristics (SmPC) (EMA, 2009) the frequency categories are respectively classified as ‘very rare’,
‘rare’, ‘uncommon’, ‘common’ and ‘very common’ when found to be< 0.01%, < 0.1%, < 1%, < 10%,≥
10%. Frequency categories obtained with the estimators will be compared to frequency categories obtained
with the benchmark estimator, i.e., the Aalen-Johansen estimator.
The comparison of the conclusions about the therapies’ safety derived from the two-sample comparisons
of the various approaches shall be compared in terms of statistical significance, clinical relevance and benefit
assessment criteria (IQWiG, 2017; Kieser and Hauschke, 2005) against the Aalen-Johansen approach as
benchmark in frequency tables.
5.4 Assessment of precision
As assessment of precision, the standard errors or the width of the confidence intervals of the estimators
will be compared to the benchmark ones. This is done in terms of plots of the ratios of the standard errors
for the methods with at most small to moderate bias. The consideration of precision is deemed useful only
in the absence of any substantial bias.
5.5 Random effects meta-analysis and meta-regression
Amore formal assessment of difference between estimators and possible factors influencing these is carried
out in form of random effects meta-analyses and meta-regressions. These will model the ratios of the
estimators considered in Section 5.1 (i.e., respective estimator divided by benchmark). The standard errors
of these ratios will be needed for the meta-analysis. As noted in Section 4.4, the derivation of these standard
errors is complicated by the dependence of the estimators. Therefore, they will be obtained with a bootstrap,
see Section 4.4.
To be more precise, the estimator of the log-ratio (log(estimator/benchmark)) θˆk is observed with
bootstrapped variance σˆ2k for each adverse event k = 1, ...,K . Then a normal-normal hierarchical model
(NNHM) (Hedges and Olkin, 2014) of the form θˆk|θk ∼ N(θk, σ
2
k) with θk|θ, ρ ∼ N(θ, ρ
2), k = 1, ...,K ,
is fitted, with ρ2 denoting the between AE heterogeneity. Thereby, between adverse events variability
is introduced via θk = θ + ǫk with ǫk ∼ N(0, ρ
2). As the main interest is in the mean parameter θ the
marginal model θˆk|θ ∼ N(θ, σ
2
k+ρ
2), k = 1, ...,K , will be used. The between adverse event variability ρ2
is estimated by the Paule-Mandel estimator as recommended by Veroniki et al. (2016). As we are also
interested in exploring any heterogeneity identified, possible sources of heterogeneity are assessed using
meta-regression models including, for example, the frequency of the adverse event and competing event
recording over time.
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The meta-analysis and meta-regression will first be performed on AE level and not on study level, i.e.,
AEs of the same study will be assumed to be independent. In a next step, as the structure of these data are
more complex than in standard meta-analyses, potentially additional hierarchy levels will be considered.
In the NNHM described above, it is assumed that it is sufficient to model the between AE heterogeneity.
However, it might be necessary to consider in addition for instance any heterogeneity between studies or
indications. Therefore, random effects not only for AE but also for study or indication are considered in
subsequent analyses to explore whether additional hierarchy levels improve model fit.
6 Discussion
We have presented the rationale and statistical concept of the empirical, meta-analytical SAVVY study
which is presently ongoing. The study aims to investigate the impact of commonly usedmethods to quantify
AE incidence which fall short of accounting for both varying follow-up times and competing risks.
The study described in this paper considers time-to-first-AE only, but not recurrent AEs. The reasons
are four-fold. Firstly, we kept in mind the ultimate goal of safety evaluation in drug development i.e. accu-
rately informing the product label adverse drug reaction section by providing the most relevant frequency
category for SmPC (Summary of Product Characteristics) or frequency for US PI (US prescribing informa-
tion). Secondly, the incidence proportion is only meaningful as an estimator of absolute AE risk for first
AEs, but not for recurrent ones. The incidence density could be computed for recurrent events in a mean-
ingful way, but the assumption of a constant AE hazard would then be an even more restrictive parametric
model (Windeler and Lange, 1995). Thirdly, censoring, varying follow-up times and competing events will
be no less important when AEs can be recurrent. For general recurrent events analyses, this has only very
recently be re-emphasized by Andersen et al. (2019). Fourthly, in a time-to-first-event analysis, the abso-
lute AE risk or cumulative AE probability, non-parametrically estimated by Aalen-Johansen, is a natural
target quantity or estimand. In a recurrent events setting, the options for statistical modelling become more
complex, because intermediate AEs will, in general, impact the incidence of subsequent AEs. One conse-
quence is that in the time-to-first-event setting, the absolute AE risk can be expressed via fully conditional
intensities, while the question of whether to use fully conditional or rather marginal approaches becomes a
more pressing question when AEs are recurrent, see again Andersen et al. (2019). It is our intention that
the SAVVY project will, in the future, also further investigate the analysis of recurrent AEs, and, to begin,
such investigations shall be informed by the results of the study described in the present paper.
The current investigations within the SAVVY project focus on analyses of individual studies. In prac-
tice, these analyses would be integrated across trials. Particular problems arise when only a small number
of trials is combined in a random effects meta-analysis (Bender et al., 2018) or the events are rare (Gu¨nhan
et al., 2019). Furthermore, strategies for signal detection in safety analyses are also not considered here, but
are subject to an ongoing research (see e.g. Gould (2018)).
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